HC Wainwright Predicts Spyglass Pharma FY2026 Earnings

Spyglass Pharma, Inc. (NASDAQ:SGP – Free Report) – Research analysts at HC Wainwright lowered their FY2026 EPS estimates for Spyglass Pharma in a research report issued to clients and investors on Thursday, November 12th. HC Wainwright analyst Y. Chen now forecasts that the company will post earnings per share of ($2.76) for the year, down from their previous estimate of ($2.52). HC Wainwright has a “Buy” rating and a $43.00 price objective on the stock. The consensus estimate for Spyglass Pharma’s current full-year earnings is ($2.77) per share. HC Wainwright also issued estimates for Spyglass Pharma’s Q4 2026 earnings at ($0.75) EPS, Q1 2027 earnings at ($0.69) EPS, Q3 2027 earnings at ($0.65) EPS, Q4 2027 earnings at ($0.66) EPS and FY2027 earnings at ($2.64) EPS.

Several other research analysts have also weighed in on the company. Raymond James Financial assumed coverage on Spyglass Pharma in a report on Friday, August 14th. They set an “outperform” rating and a $39.00 target price on the stock. Wall Street Zen upgraded Spyglass Pharma from a “sell” rating to a “hold” rating in a report on Saturday, October 31st. Weiss Ratings raised Spyglass Pharma from a “sell (e)” rating to a “sell (d-)” rating in a research report on Friday. Stifel Nicolaus raised their price target on Spyglass Pharma from $42.00 to $44.00 and gave the stock a “buy” rating in a research report on Friday, November 13th. Finally, Citigroup lifted their price objective on Spyglass Pharma from $42.00 to $45.00 and gave the company a “buy” rating in a report on Friday, November 13th. Seven equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus target price of $45.83.

Read Our Latest Stock Report on SGP

Spyglass Pharma Stock Performance

SGP opened at $31.43 on Monday. Spyglass Pharma has a 12 month low of $17.06 and a 12 month high of $39.92. The company has a fifty day simple moving average of $28.90 and a 200 day simple moving average of $24.90.

Spyglass Pharma (NASDAQ:SGP – Get Free Report) last announced its quarterly earnings results on Thursday, November 12th. The company reported ($0.73) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.66) by ($0.07).

Institutional Inflows and Outflows

Hedge funds have recently modified their holdings of the company. Bank of New York Mellon Corp acquired a new stake in Spyglass Pharma in the 2nd quarter valued at approximately $533,000. Bank of America Corp DE acquired a new position in Spyglass Pharma during the 1st quarter worth approximately $726,000. The Manufacturers Life Insurance Company acquired a new position in Spyglass Pharma during the 1st quarter worth approximately $308,000. First Light Asset Management LLC acquired a new position in Spyglass Pharma during the 1st quarter worth approximately $9,716,000. Finally, Affinity Asset Advisors LLC bought a new position in shares of Spyglass Pharma during the 1st quarter worth approximately $6,478,000.

Spyglass Pharma Company Profile

(Get Free Report)

SpyGlass Pharma is a clinical-stage ophthalmology company developing sustained-release drug delivery systems for chronic eye diseases. Its research is focused on reducing reliance on patients’ regular use of eye drops. The company’s lead program is a bimatoprost drug delivery system being developed to treat glaucoma and ocular hypertension. Bimatoprost is a medication used to lower eye pressure, and SpyGlass is studying a delivery approach intended to provide treatment over an extended period. SpyGlass Pharma’s work centers on advancing this ophthalmic delivery platform and its lead program through clinical development.

Featured Articles

Earnings History and Estimates for Spyglass Pharma (NASDAQ:SGP)

Receive News & Ratings for Spyglass Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Spyglass Pharma and related companies with MarketBeat.com's FREE daily email newsletter.